Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Retained Earnings (2017 - 2025)

Protagonist Therapeutics' Retained Earnings history spans 9 years, with the latest figure at $641000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 100.19% year-over-year to $641000.0; the TTM value through Dec 2025 reached $641000.0, up 100.19%, while the annual FY2025 figure was $641000.0, 100.19% up from the prior year.
  • Retained Earnings for Q4 2025 was $641000.0 at Protagonist Therapeutics, up from -$426.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.3 million in Q3 2024 and bottomed at -$615.7 million in Q4 2023.
  • The 5-year median for Retained Earnings is -$304000.0 (2022), against an average of -$135.1 million.
  • The largest annual shift saw Retained Earnings plummeted 171406.96% in 2023 before it surged 885.88% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$409.4 million in 2021, then soared by 99.91% to -$359000.0 in 2022, then tumbled by 171406.96% to -$615.7 million in 2023, then surged by 44.69% to -$340.5 million in 2024, then skyrocketed by 100.19% to $641000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Retained Earnings are $641000.0 (Q4 2025), -$426.3 million (Q3 2025), and -$15000.0 (Q2 2025).